Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016

 

Rating

4.1 Star Rating for report Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016
4.1 / 5 stars rating
Pages: 63
Price: $2000.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape.

Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8826IDBPituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Revie...Dec 2016
Report... 05IB-GMDHC8814IDBHyperglycemia - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8807IDBFamilial Amyloid Neuropathies - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8762IDBHeterozygous familial hypercholesterolemia (heFH) - Pipeline Rev...Nov 2016
Report... 05IB-GMDHC8737IDBHomozygous Familial Hypercholesterolemia (HoFH) - Pipeline Revie...Nov 2016
Report... 05IB-GMDHC8697IDBHypercholesterolemia - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8696IDBDiabetic Foot Ulcers - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8653IDBDiabetic Neuropathy - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8654IDBDiabetic Retinopathy - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8770IDBType 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016Nov 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-09-30 

Report: Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Proliferative Diabetic Retinopathy (PDR) Overview 6
Therapeutics Development 7
Pipeline Products for Proliferative Diabetic Retinopathy (PDR) - Overview 7
Proliferative Diabetic Retinopathy (PDR) - Therapeutics under Development by Companies 8
Proliferative Diabetic Retinopathy (PDR) - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Proliferative Diabetic Retinopathy (PDR) - Products under Development by Companies 11
Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development 12
Acucela Inc. 12
Aerie Pharmaceuticals, Inc. 13
Antisense Therapeutics Limited 14
Icon Bioscience, Inc. 15
OcuCure Therapeutics, Inc. 16
Ohr Pharmaceutical Inc. 17
PanOptica, Inc. 18
Ribomic Inc. 19
ThromboGenics NV 20
Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
AR-13154 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
atesidorsen sodium - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
cyclosporine - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
emixustat hydrochloride - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
OC-10X - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ocriplasmin - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
OLX-302 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
PAN-90806 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
RBM-008 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
squalamine lactate - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Proliferative Diabetic Retinopathy (PDR) - Dormant Projects 60
Proliferative Diabetic Retinopathy (PDR) - Product Development Milestones 61
Featured News & Press Releases 61
May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63
 

List of Tables

List of Tables
Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Acucela Inc., H2 2016 12
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 13
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Antisense Therapeutics Limited, H2 2016 14
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Icon Bioscience, Inc., H2 2016 15
Proliferative Diabetic Retinopathy (PDR) - Pipeline by OcuCure Therapeutics, Inc., H2 2016 16
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ohr Pharmaceutical Inc., H2 2016 17
Proliferative Diabetic Retinopathy (PDR) - Pipeline by PanOptica, Inc., H2 2016 18
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ribomic Inc., H2 2016 19
Proliferative Diabetic Retinopathy (PDR) - Pipeline by ThromboGenics NV, H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Proliferative Diabetic Retinopathy (PDR) - Dormant Projects, H2 2016 60
 

List of Figures

List of Figures
Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Top 10 Targets, H2 2016 22
Number of Products by Stage and Top 10 Targets, H2 2016 22
Number of Products by Top 10 Mechanism of Actions, H2 2016 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 24
Number of Products by Routes of Administration, H2 2016 26
Number of Products by Stage and Routes of Administration, H2 2016 26
Number of Products by Molecule Types, H2 2016 28
Number of Products by Stage and Molecule Types, H2 2016 28
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 4 and 1 respectively for Proliferative Diabetic Retinopathy (PDR).

Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Metabolic Disorders 
Pages: 63 

Companies Featured

Acucela Inc. Aerie Pharmaceuticals, Inc. Antisense Therapeutics Limited Icon Bioscience, Inc. OcuCure Therapeutics, Inc. Ohr Pharmaceutical Inc. PanOptica, Inc. Ribomic Inc. ThromboGenics NV

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8826IDBPituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Revie...Dec 2016
Report... 05IB-GMDHC8814IDBHyperglycemia - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8807IDBFamilial Amyloid Neuropathies - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8762IDBHeterozygous familial hypercholesterolemia (heFH) - Pipeline Rev...Nov 2016
Report... 05IB-GMDHC8737IDBHomozygous Familial Hypercholesterolemia (HoFH) - Pipeline Revie...Nov 2016
Report... 05IB-GMDHC8697IDBHypercholesterolemia - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8696IDBDiabetic Foot Ulcers - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8653IDBDiabetic Neuropathy - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8654IDBDiabetic Retinopathy - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8770IDBType 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016Nov 2016

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016

Report 05IB-GMDHC8509IDB has a rating of 80.2 percent
Figure of merit assessment for report 05IB-GMDHC8509IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7184

Taxonomy Location

The taxonomy on the left shows the ancestors of the Metabolic Disorders node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Metabolic Disorders

Metabolic Disorders

 

Healthcare Disorders

Healthcare Disorders

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8509IDB

 
Licence: Single User
Price: $2000.00
 
VAT: 0.0% 
Total: $2000.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [2.79650s]

--